{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["SARS-CoV-2", "autodocking", "glycyrrhizin", "surface plasmon resonance"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "34684671", "DateCompleted": {"Year": "2021", "Month": "10", "Day": "27"}, "DateRevised": {"Year": "2024", "Month": "04", "Day": "03"}, "Article": {"ArticleDate": [{"Year": "2021", "Month": "10", "Day": "09"}], "Language": ["eng"], "ELocationID": ["6090", "10.3390/molecules26206090"], "Journal": {"ISSN": "1420-3049", "JournalIssue": {"Volume": "26", "Issue": "20", "PubDate": {"Year": "2021", "Month": "Oct", "Day": "09"}}, "Title": "Molecules (Basel, Switzerland)", "ISOAbbreviation": "Molecules"}, "ArticleTitle": "Glycyrrhizic Acid Inhibits SARS-CoV-2 Infection by Blocking Spike Protein-Mediated Cell Attachment.", "Abstract": {"AbstractText": ["Glycyrrhizic acid (GA), also known as glycyrrhizin, is a triterpene glycoside isolated from plants of <i>Glycyrrhiza</i> species (licorice). GA possesses a wide range of pharmacological and antiviral activities against enveloped viruses including severe acute respiratory syndrome (SARS) virus. Since the S protein (S) mediates SARS coronavirus 2 (SARS-CoV-2) cell attachment and cell entry, we assayed the GA effect on SARS-CoV-2 infection using an S protein-pseudotyped lentivirus (Lenti-S). GA treatment dose-dependently blocked Lenti-S infection. We showed that incubation of Lenti-S virus, but not the host cells with GA prior to the infection, reduced Lenti-S infection, indicating that GA targeted the virus for infection. Surface plasmon resonance measurement showed that GA interacted with a recombinant S protein and blocked S protein binding to host cells. Autodocking analysis revealed that the S protein has several GA-binding pockets including one at the interaction interface to the receptor angiotensin-converting enzyme 2 (ACE2) and another at the inner side of the receptor-binding domain (RBD) which might impact the close-to-open conformation change of the S protein required for ACE2 interaction. In addition to identifying GA antiviral activity against SARS-CoV-2, the study linked GA antiviral activity to its effect on virus cell binding."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Pharmaceutical Biotechnology, Medical School, Nanjing University, Nanjing 210093, China."}, {"Identifier": [], "Affiliation": "Jiangsu Key Laboratory of Molecular Medicine, Medical School, Nanjing University, Nanjing 210093, China."}, {"Identifier": [], "Affiliation": "Jiangsu Topcel Biological Technology Co., Ltd., Nanjing 210093, China."}], "LastName": "Li", "ForeName": "Jingjing", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Pharmaceutical Biotechnology, Medical School, Nanjing University, Nanjing 210093, China."}, {"Identifier": [], "Affiliation": "Jiangsu Key Laboratory of Molecular Medicine, Medical School, Nanjing University, Nanjing 210093, China."}, {"Identifier": [], "Affiliation": "Yancheng Medical Research Centre, Medical School, Nanjing University, Yancheng 224000, China."}], "LastName": "Xu", "ForeName": "Dongge", "Initials": "D"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Pharmaceutical Biotechnology, Medical School, Nanjing University, Nanjing 210093, China."}, {"Identifier": [], "Affiliation": "Jiangsu Key Laboratory of Molecular Medicine, Medical School, Nanjing University, Nanjing 210093, China."}, {"Identifier": [], "Affiliation": "Institute of Medical Virology, Nanjing Drum Tower Hospital, Medical School, Nanjing University, Nanjing 210093, China."}], "LastName": "Wang", "ForeName": "Lingling", "Initials": "L"}, {"Identifier": ["0000-0002-2917-7286"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Pharmaceutical Biotechnology, Medical School, Nanjing University, Nanjing 210093, China."}, {"Identifier": [], "Affiliation": "Jiangsu Key Laboratory of Molecular Medicine, Medical School, Nanjing University, Nanjing 210093, China."}, {"Identifier": [], "Affiliation": "Yancheng Medical Research Centre, Medical School, Nanjing University, Yancheng 224000, China."}], "LastName": "Zhang", "ForeName": "Mengyu", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources, School of Chemistry and Pharmaceutical Sciences, Guangxi Normal University, Guilin 541006, China."}], "LastName": "Zhang", "ForeName": "Guohai", "Initials": "G"}, {"Identifier": ["0000-0002-3065-1336"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Pharmaceutical Biotechnology, Medical School, Nanjing University, Nanjing 210093, China."}, {"Identifier": [], "Affiliation": "Jiangsu Key Laboratory of Molecular Medicine, Medical School, Nanjing University, Nanjing 210093, China."}, {"Identifier": [], "Affiliation": "Shenzhen Institute of Nanjing University, Shenzhen 518000, China."}], "LastName": "Li", "ForeName": "Erguang", "Initials": "E"}, {"Identifier": ["0000-0002-2138-3421"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Pharmaceutical Biotechnology, Medical School, Nanjing University, Nanjing 210093, China."}, {"Identifier": [], "Affiliation": "Jiangsu Key Laboratory of Molecular Medicine, Medical School, Nanjing University, Nanjing 210093, China."}, {"Identifier": [], "Affiliation": "Yancheng Medical Research Centre, Medical School, Nanjing University, Yancheng 224000, China."}], "LastName": "He", "ForeName": "Susu", "Initials": "S"}], "GrantList": [{"GrantID": "81871636", "Agency": "National Natural Science Foundation of China", "Country": ""}, {"GrantID": "BK20200316", "Agency": "Natural Science Foundation of Jiangsu Province", "Country": ""}, {"GrantID": "2017BN04", "Agency": "Ningxia Hui Autonomous Region", "Country": ""}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Molecules", "NlmUniqueID": "100964009", "ISSNLinking": "1420-3049"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antiviral Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Spike Glycoprotein, Coronavirus"}, {"RegistryNumber": "0", "NameOfSubstance": "spike protein, SARS-CoV-2"}, {"RegistryNumber": "6FO62043WK", "NameOfSubstance": "Glycyrrhizic Acid"}, {"RegistryNumber": "EC 3.4.17.23", "NameOfSubstance": "ACE2 protein, human"}, {"RegistryNumber": "EC 3.4.17.23", "NameOfSubstance": "Angiotensin-Converting Enzyme 2"}], "MeshHeadingList": [{"QualifierName": ["chemistry", "metabolism"], "DescriptorName": "Angiotensin-Converting Enzyme 2"}, {"QualifierName": ["chemistry", "metabolism", "pharmacology", "therapeutic use"], "DescriptorName": "Antiviral Agents"}, {"QualifierName": [], "DescriptorName": "Binding Sites"}, {"QualifierName": ["virology"], "DescriptorName": "COVID-19"}, {"QualifierName": ["chemistry", "metabolism", "pharmacology", "therapeutic use"], "DescriptorName": "Glycyrrhizic Acid"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Molecular Docking Simulation"}, {"QualifierName": [], "DescriptorName": "Protein Binding"}, {"QualifierName": ["isolation & purification", "metabolism"], "DescriptorName": "SARS-CoV-2"}, {"QualifierName": ["chemistry", "metabolism"], "DescriptorName": "Spike Glycoprotein, Coronavirus"}, {"QualifierName": ["drug effects"], "DescriptorName": "Virus Internalization"}, {"QualifierName": [], "DescriptorName": "COVID-19 Drug Treatment"}], "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Li T., Lu H., Zhang W. Clinical observation and management of COVID-19 patients. Emerg. Microbes Infect. 2020;9:687\u2013690. doi: 10.1080/22221751.2020.1741327.", "ArticleIdList": ["10.1080/22221751.2020.1741327", "PMC7103696", "32208840"]}, {"Citation": "Drayman N., DeMarco J.K., Jones K.A., Azizi S.A., Froggatt H.M., Tan K., Maltseva N.I., Chen S., Nicolaescu V., Dvorkin S., et al. Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2. Science. 2021;373:931\u2013936. doi: 10.1126/science.abg5827.", "ArticleIdList": ["10.1126/science.abg5827", "PMC8809056", "34285133"]}, {"Citation": "National Health Commission of the People\u2019s Republic of China, Diagnosis and Treatment Protocol for COVID-19 Patients (Tentative 8th Edition)  [(accessed on 26 September 2021)].  Available online:  http://regional.chinadaily.com.cn/pdf/DiagnosisandTreatmentProtocolforCOVID-19Patients(Tentative8thEdition).pdf."}, {"Citation": "Fiore C., Eisenhut M., Krausse R., Ragazzi E., Pellati D., Armanini D., Bielenberg J. Antiviral effects of Glycyrrhiza species. Phytother. Res. 2008;22:141\u2013148. doi: 10.1002/ptr.2295.", "ArticleIdList": ["10.1002/ptr.2295", "PMC7167979", "17886224"]}, {"Citation": "Shibata S. A drug over the millennia: Pharmacognosy, chemistry, and pharmacology of licorice. Yakugaku Zasshi. 2000;120:849\u2013862. doi: 10.1248/yakushi1947.120.10_849.", "ArticleIdList": ["10.1248/yakushi1947.120.10_849", "11082698"]}, {"Citation": "Fiore C., Eisenhut M., Ragazzi E., Zanchin G., Armanini D. A history of the therapeutic use of liquorice in Europe. J. Ethnopharmacol. 2005;99:317\u2013324. doi: 10.1016/j.jep.2005.04.015.", "ArticleIdList": ["10.1016/j.jep.2005.04.015", "PMC7125727", "15978760"]}, {"Citation": "Gomaa A.A., Abdel-Wadood Y.A. The potential of glycyrrhizin and licorice extract in combating COVID-19 and associated conditions. Phytomed. Plus. 2021;1:100043. doi: 10.1016/j.phyplu.2021.100043.", "ArticleIdList": ["10.1016/j.phyplu.2021.100043", "PMC7886629", "35399823"]}, {"Citation": "Rauchensteiner F., Matsumura Y., Yamamoto Y., Yamaji S., Tani T. Analysis and comparison of Radix Glycyrrhizae (licorice) from Europe and China by capillary-zone electrophoresis (CZE) J. Pharm. Biomed. Anal. 2005;38:594\u2013600. doi: 10.1016/j.jpba.2005.01.038.", "ArticleIdList": ["10.1016/j.jpba.2005.01.038", "15967286"]}, {"Citation": "Isbrucker R.A., Burdock G.A. Risk and safety assessment on the consumption of Licorice root (Glycyrrhiza sp.), its extract and powder as a food ingredient, with emphasis on the pharmacology and toxicology of glycyrrhizin. Regul. Toxicol. Pharmacol. 2006;46:167\u2013192. doi: 10.1016/j.yrtph.2006.06.002.", "ArticleIdList": ["10.1016/j.yrtph.2006.06.002", "16884839"]}, {"Citation": "Pompei R., Flore O., Marccialis M.A., Pani A., Loddo B. Glycyrrhizic acid inhibits virus growth and inactivates virus particles. Nature. 1979;281:689\u2013690. doi: 10.1038/281689a0.", "ArticleIdList": ["10.1038/281689a0", "233133"]}, {"Citation": "Pompei R., Laconi S., Ingianni A. Antiviral properties of glycyrrhizic acid and its semisynthetic derivatives. Mini Rev. Med. Chem. 2009;9:996\u20131001. doi: 10.2174/138955709788681636.", "ArticleIdList": ["10.2174/138955709788681636", "19601894"]}, {"Citation": "Cinatl J., Morgenstern B., Bauer G., Chandra P., Rabenau H., Doerr H.W. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet. 2003;361:2045\u20132046. doi: 10.1016/S0140-6736(03)13615-X.", "ArticleIdList": ["10.1016/S0140-6736(03)13615-X", "PMC7112442", "12814717"]}, {"Citation": "Chrzanowski J., Chrzanowska A., Grabon W. Glycyrrhizin: An old weapon against a novel coronavirus. Phytother. Res. 2021;35:629\u2013636. doi: 10.1002/ptr.6852.", "ArticleIdList": ["10.1002/ptr.6852", "32902005"]}, {"Citation": "Jezova D., Karailiev P., Karailievova L., Puhova A., Murck H. Food Enrichment with Glycyrrhiza glabra Extract Suppresses ACE2 mRNA and Protein Expression in Rats-Possible Implications for COVID-19. Nutrients. 2021;13:2321. doi: 10.3390/nu13072321.", "ArticleIdList": ["10.3390/nu13072321", "PMC8308790", "34371831"]}, {"Citation": "Fukushi S., Mizutani T., Saijo M., Matsuyama S., Miyajima N., Taguchi F., Itamura S., Kurane I., Morikawa S. Vesicular stomatitis virus pseudotyped with severe acute respiratory syndrome coronavirus spike protein. J. Gen. Virol. 2005;86:2269\u20132274. doi: 10.1099/vir.0.80955-0.", "ArticleIdList": ["10.1099/vir.0.80955-0", "16033974"]}, {"Citation": "Lukassen S., Chua R.L., Trefzer T., Kahn N.C., Schneider M.A., Muley T., Winter H., Meister M., Veith C., Boots A.W., et al. SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. EMBO J. 2020;39:e105114. doi: 10.15252/embj.2020105114.", "ArticleIdList": ["10.15252/embj.2020105114", "PMC7232010", "32246845"]}, {"Citation": "Li S.L., Zhang X.Y., Ling H., Ikeda J., Shirato K., Hattori T. A VSV-G pseudotyped HIV vector mediates efficient transduction of human pulmonary artery smooth muscle cells. Microbiol. Immunol. 2000;44:1019\u20131025. doi: 10.1111/j.1348-0421.2000.tb02598.x.", "ArticleIdList": ["10.1111/j.1348-0421.2000.tb02598.x", "11220675"]}, {"Citation": "Li W., Moore M.J., Vasilieva N., Sui J., Wong S.K., Berne M.A., Somasundaran M., Sullivan J.L., Luzuriaga K., Greenough T.C., et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450\u2013454. doi: 10.1038/nature02145.", "ArticleIdList": ["10.1038/nature02145", "PMC7095016", "14647384"]}, {"Citation": "Trott O., Olson A.J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 2010;31:455\u2013461. doi: 10.1002/jcc.21334.", "ArticleIdList": ["10.1002/jcc.21334", "PMC3041641", "19499576"]}, {"Citation": "Wrapp D., Wang N., Corbett K.S., Goldsmith J.A., Hsieh C.L., Abiona O., Graham B.S., McLellan J.S. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260\u20131263. doi: 10.1126/science.abb2507.", "ArticleIdList": ["10.1126/science.abb2507", "PMC7164637", "32075877"]}, {"Citation": "Morris G.M., Huey R., Lindstrom W., Sanner M.F., Belew R.K., Goodsell D.S., Olson A.J. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem. 2009;30:2785\u20132791. doi: 10.1002/jcc.21256.", "ArticleIdList": ["10.1002/jcc.21256", "PMC2760638", "19399780"]}, {"Citation": "Ahmad S., Waheed Y., Abro A., Abbasi S.W., Ismail S. Molecular screening of glycyrrhizin-based inhibitors against ACE2 host receptor of SARS-CoV-2. J. Mol. Model. 2021;27:206. doi: 10.1007/s00894-021-04816-y.", "ArticleIdList": ["10.1007/s00894-021-04816-y", "PMC8225399", "34169390"]}, {"Citation": "Ye C., Gao M., Lin W., Yu K., Li P., Chen G. Theoretical Study of the anti-NCP Molecular Mechanism of Traditional Chinese Medicine Lianhua-Qingwen Formula (LQF)  [(accessed on 26 September 2021)];ChemRxiv. 2020  Available online:  https://chemrxiv.org/engage/chemrxiv/article-details/60c74908ee74301c74485bc74799cf."}, {"Citation": "Walls A.C., Park Y.J., Tortorici M.A., Wall A., McGuire A.T., Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;181:281\u2013292. doi: 10.1016/j.cell.2020.02.058.", "ArticleIdList": ["10.1016/j.cell.2020.02.058", "PMC7102599", "32155444"]}, {"Citation": "Xu C., Wang Y., Liu C., Zhang C., Han W., Hong X., Wang Y., Hong Q., Wang S., Zhao Q., et al. Conformational dynamics of SARS-CoV-2 trimeric spike glycoprotein in complex with receptor ACE2 revealed by cryo-EM. Sci. Adv. 2021;7:eabe5575. doi: 10.1126/sciadv.abe5575.", "ArticleIdList": ["10.1126/sciadv.abe5575", "PMC7775788", "33277323"]}, {"Citation": "Li B., Huang H., Wang X., Yan W., Huo L. Possible Mechanisms of Glycyrrhizic Acid Preparation Against Coronavirus Disease 2019. J. Pract. Card. Cereb. Pneumal Vasc. Dis. 2020;28:13\u201318. (In Chinese)"}, {"Citation": "Yu S., Zhu Y., Xu J., Yao G., Zhang P., Wang M., Zhao Y., Lin G., Chen H., Chen L., et al. Glycyrrhizic acid exerts inhibitory activity against the spike protein of SARS-CoV-2. Phytomedicine. 2021;85:153364. doi: 10.1016/j.phymed.2020.153364.", "ArticleIdList": ["10.1016/j.phymed.2020.153364", "PMC7531286", "33041173"]}, {"Citation": "Gowda P., Patrick S., Joshi S.D., Kumawat R.K., Sen E. Glycyrrhizin prevents SARS-CoV-2 S1 and Orf3a induced high mobility group box 1 (HMGB1) release and inhibits viral replication. Cytokine. 2021;142:155496. doi: 10.1016/j.cyto.2021.155496.", "ArticleIdList": ["10.1016/j.cyto.2021.155496", "PMC7953444", "33773396"]}, {"Citation": "van de Sand L., Bormann M., Alt M., Schipper L., Heilingloh C.S., Steinmann E., Todt D., Dittmer U., Elsner C., Witzke O., et al. Glycyrrhizin Effectively Inhibits SARS-CoV-2 Replication by Inhibiting the Viral Main Protease. Viruses. 2021;13:609. doi: 10.3390/v13040609.", "ArticleIdList": ["10.3390/v13040609", "PMC8066091", "33918301"]}, {"Citation": "Zheng W., Huang X., Lai Y., Liu X., Jiang Y., Zhan S. Glycyrrhizic Acid for COVID-19: Findings of Targeting Pivotal Inflammatory Pathways Triggered by SARS-CoV-2. Front. Pharmacol. 2021;12:631206. doi: 10.3389/fphar.2021.631206.", "ArticleIdList": ["10.3389/fphar.2021.631206", "PMC8223069", "34177566"]}, {"Citation": "Nie Y., Wang P., Shi X., Wang G., Chen J., Zheng A., Wang W., Wang Z., Qu X., Luo M., et al. Highly infectious SARS-CoV pseudotyped virus reveals the cell tropism and its correlation with receptor expression. Biochem. Biophys. Res. Commun. 2004;321:994\u20131000. doi: 10.1016/j.bbrc.2004.07.060.", "ArticleIdList": ["10.1016/j.bbrc.2004.07.060", "PMC7092805", "15358126"]}, {"Citation": "Wang J., Deng F., Ye G., Dong W., Zheng A., He Q., Peng G. Comparison of lentiviruses pseudotyped with S proteins from coronaviruses and cell tropisms of porcine coronaviruses. Virol. Sin. 2016;31:49\u201356. doi: 10.1007/s12250-015-3690-4.", "ArticleIdList": ["10.1007/s12250-015-3690-4", "PMC7090623", "26908211"]}, {"Citation": "Grehan K., Ferrara F., Temperton N. An optimised method for the production of MERS-CoV spike expressing viral pseudotypes. MethodsX. 2015;2:379\u2013384. doi: 10.1016/j.mex.2015.09.003.", "ArticleIdList": ["10.1016/j.mex.2015.09.003", "PMC4625112", "26587388"]}, {"Citation": "Ou X., Liu Y., Lei X., Li P., Mi D., Ren L., Guo L., Guo R., Chen T., Hu J., et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. Commun. 2020;11:1620. doi: 10.1038/s41467-020-15562-9.", "ArticleIdList": ["10.1038/s41467-020-15562-9", "PMC7100515", "32221306"]}, {"Citation": "Chen H., Du Q. Potential natural compounds for preventing SARS-CoV-2 (2019-nCoV) infection.  [(accessed on 26 September 2021)];Preprints. 2020  Available online:  https://www.preprints.org/manuscript/202001.200358/v202002."}, {"Citation": "Sinha S.K., Prasad S.K., Islam M.A., Gurav S.S., Patil R.B., AlFaris N.A., Aldayel T.S., AlKehayez N.M., Wabaidur S.M., Shakya A. Identification of bioactive compounds from Glycyrrhiza glabra as possible inhibitor of SARS-CoV-2 spike glycoprotein and non-structural protein-15: A pharmacoinformatics study. J. Biomol. Struct. Dyn. 2020;39:4686\u20134700. doi: 10.1080/07391102.2020.1779132.", "ArticleIdList": ["10.1080/07391102.2020.1779132", "PMC7309308", "32552462"]}, {"Citation": "Zhao Z., Xiao Y., Xu L., Liu Y., Jiang G., Wang W., Li B., Zhu T., Tan Q., Tang L., et al. Glycyrrhizic Acid Nanoparticles as Antiviral and Anti-inflammatory Agents for COVID-19 Treatment. ACS Appl. Mater. Interfaces. 2021;13:20995\u201321006. doi: 10.1021/acsami.1c02755.", "ArticleIdList": ["10.1021/acsami.1c02755", "33930273"]}, {"Citation": "Mollica L., De Marchis F., Spitaleri A., Dallacosta C., Pennacchini D., Zamai M., Agresti A., Trisciuoglio L., Musco G., Bianchi M.E. Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chem. Biol. 2007;14:431\u2013441. doi: 10.1016/j.chembiol.2007.03.007.", "ArticleIdList": ["10.1016/j.chembiol.2007.03.007", "17462578"]}, {"Citation": "Kim S.W., Jin Y., Shin J.H., Kim I.D., Lee H.K., Park S., Han P.L., Lee J.K. Glycyrrhizic acid affords robust neuroprotection in the postischemic brain via anti-inflammatory effect by inhibiting HMGB1 phosphorylation and secretion. Neurobiol. Dis. 2012;46:147\u2013156. doi: 10.1016/j.nbd.2011.12.056.", "ArticleIdList": ["10.1016/j.nbd.2011.12.056", "22266336"]}, {"Citation": "Yang P.S., Kim D.H., Lee Y.J., Lee S.E., Kang W.J., Chang H.J., Shin J.S. Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats. Respir. Res. 2014;15:148. doi: 10.1186/s12931-014-0148-4.", "ArticleIdList": ["10.1186/s12931-014-0148-4", "PMC4248446", "25420924"]}, {"Citation": "Marandici A., Monder C. Inhibition by glycyrrhetinic acid of rat tissue 11 beta-hydroxysteroid dehydrogenase in vivo. Steroids. 1993;58:153\u2013156. doi: 10.1016/0039-128X(93)90062-R.", "ArticleIdList": ["10.1016/0039-128X(93)90062-R", "8493704"]}, {"Citation": "Wang C.Y., Kao T.C., Lo W.H., Yen G.C. Glycyrrhizic acid and 18beta-glycyrrhetinic acid modulate lipopolysaccharide-induced inflammatory response by suppression of NF-kappaB through PI3K p110delta and p110gamma inhibitions. J. Agric. Food Chem. 2011;59:7726\u20137733. doi: 10.1021/jf2013265.", "ArticleIdList": ["10.1021/jf2013265", "21644799"]}, {"Citation": "Ko\u010devar Glava\u010d N., Kreft S. Excretion profile of glycyrrhizin metabolite in human urine. Food Chem. 2012;131:305\u2013308. doi: 10.1016/j.foodchem.2011.08.081.", "ArticleIdList": ["10.1016/j.foodchem.2011.08.081"]}, {"Citation": "Hoever G., Baltina L., Michaelis M., Kondratenko R., Baltina L., Tolstikov G.A., Doerr H.W., Cinatl J., Jr. Antiviral activity of glycyrrhizic acid derivatives against SARS-coronavirus. J. Med. Chem. 2005;48:1256\u20131259. doi: 10.1021/jm0493008.", "ArticleIdList": ["10.1021/jm0493008", "15715493"]}, {"Citation": "Harada S. The broad anti-viral agent glycyrrhizin directly modulates the fluidity of plasma membrane and HIV-1 envelope. Biochem. J. 2005;392:191\u2013199. doi: 10.1042/BJ20051069.", "ArticleIdList": ["10.1042/BJ20051069", "PMC1317678", "16053446"]}, {"Citation": "Ralla T., Salminen H., Braun K., Edelmann M., Dawid C., Hofmann T., Weiss J. Investigations into the Structure-Function Relationship of the Naturally-Derived Surfactant Glycyrrhizin: Emulsion Stability. Food Biophys. 2020;15:288\u2013296. doi: 10.1007/s11483-020-09624-0.", "ArticleIdList": ["10.1007/s11483-020-09624-0"]}, {"Citation": "Selyutina O.Y., Apanasenko I.E., Kim A.V., Shelepova E.A., Khalikov S.S., Polyakov N.E. Spectroscopic and molecular dynamics characterization of glycyrrhizin membrane-modifying activity. Colloids Surf. B Biointerfaces. 2016;147:459\u2013466. doi: 10.1016/j.colsurfb.2016.08.037.", "ArticleIdList": ["10.1016/j.colsurfb.2016.08.037", "27580071"]}, {"Citation": "Predmore A., Li J. Enhanced removal of a human norovirus surrogate from fresh vegetables and fruits by a combination of surfactants and sanitizers. Appl. Environ. Microbiol. 2011;77:4829\u20134838. doi: 10.1128/AEM.00174-11.", "ArticleIdList": ["10.1128/AEM.00174-11", "PMC3147408", "21622782"]}, {"Citation": "Bailly C., Vergoten G. Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome? Pharmacol. Ther. 2020;214:107618. doi: 10.1016/j.pharmthera.2020.107618.", "ArticleIdList": ["10.1016/j.pharmthera.2020.107618", "PMC7311916", "32592716"]}, {"Citation": "Selyutina O.Y., Shelepova E.A., Paramonova E.D., Kichigina L.A., Khalikov S.S., Polyakov N.E. Glycyrrhizin-induced changes in phospholipid dynamics studied by (1)H NMR and MD simulation. Arch. Biochem. Biophys. 2020;686:108368. doi: 10.1016/j.abb.2020.108368.", "ArticleIdList": ["10.1016/j.abb.2020.108368", "32315654"]}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "8", "Day": "10"}, {"Year": "2021", "Month": "9", "Day": "27"}, {"Year": "2021", "Month": "9", "Day": "30"}, {"Year": "2021", "Month": "10", "Day": "23", "Hour": "1", "Minute": "19"}, {"Year": "2021", "Month": "10", "Day": "24", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "10", "Day": "28", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "10", "Day": "9"}], "PublicationStatus": "epublish", "ArticleIdList": ["34684671", "PMC8539771", "10.3390/molecules26206090", "molecules26206090"]}}], "PubmedBookArticle": []}